Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment
Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li
Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li
View: Text | PDF
Research Article Dermatology Oncology

Keratinocyte-derived cytokine TSLP promotes growth and metastasis of melanoma by regulating the tumor-associated immune microenvironment

  • Text
  • PDF
Abstract

Malignant melanoma is a major public health issue displaying frequent resistance to targeted therapy and immunotherapy. A major challenge lies in better understanding how melanoma cells evade immune elimination and how tumor growth and metastasis is facilitated by the tumor microenvironment. Here, we show that expression of the cytokine thymic stromal lymphopoietin (TSLP) by epidermal keratinocytes is induced by cutaneous melanoma in both mice and humans. Using genetically engineered models of melanoma and tumor cell grafting combined with TSLP-KO or overexpression, we defined a crosstalk between melanoma cells, keratinocytes, and immune cells in establishing a tumor-promoting microenvironment. Keratinocyte-derived TSLP is induced by signals derived from melanoma cells and subsequently acts via immune cells to promote melanoma progression and metastasis. Furthermore, we show that TSLP signals through TSLP receptor–expressing (TSLPR-expressing) DCs to play an unrecognized role in promoting GATA3+ Tregs expressing a gene signature including ST2, CCR8, ICOS, PD-1, CTLA-4, and OX40 and exhibiting a potent suppressive activity on CD8+ T cell proliferation and IFN-γ production. An analogous population of GATA3-expressing Tregs was also identified in human melanoma tumors. Our study provides insights into the role of TSLP in programming a protumoral immune microenvironment in cutaneous melanoma.

Authors

Wenjin Yao, Beatriz German, Dounia Chraa, Antoine Braud, Cecile Hugel, Pierre Meyer, Guillaume Davidson, Patrick Laurette, Gabrielle Mengus, Eric Flatter, Pierre Marschall, Justine Segaud, Marine Guivarch, Pierre Hener, Marie-Christine Birling, Dan Lipsker, Irwin Davidson, Mei Li

×

Figure 2

MC903-induced TSLP overexpression promotes and accelerates the growth and metastasis of mouse melanoma.

Options: View larger image (or click on image) Download as PowerPoint
MC903-induced TSLP overexpression promotes and accelerates the growth an...
(A) Experimental protocol. Dorsal part of ears of mice were topically treated with 4-hydroxytamoxifen (4-HT) for 3 days (D0–D2). Starting from D4, right ears (RE) were treated with MC903 (2 nmol), while left ears (LE) were treated with ethanol (EtOH, vehicle control) 3 times per week (wk) for 3 wks. Ears were analyzed at different time points. (B) Appearance of EtOH-treated LE and MC903-treated RE from CT, Braf, and Braf/Tslp–/– mice at D40. (C) H&E staining of ear sections from EtOH-treated CT, MC903-treated CT, MC903-treated Braf, and MC903-treated Braf/Tslp–/– mice. (D) Appearance of EtOH- and MC903-treated ears of CT and Braf/Pten mice at the indicated time points. (E) H&E staining of ear sections from EtOH- or MC903-treated Braf/Pten mice at D25 and D45. Note that the magnifications for photos of D25 and D45 are different, indicated by scale bars (50 μm for all). Black arrow points to the formation of solid tumor in MC903-treated Braf/Pten ears at D45. (F) TSLP protein levels in Braf/Pten mouse ears treated with EtOH or different doses of MC903 at D30. (G) IHC of SOX10 on ear sections of Braf/Pten mice treated with EtOH and different doses of MC903, at D30. Blue arrows point to one of the Sox10+ melanoma cells (in dark red). (H and I) Appearance of ear-draining lymph nodes (ELNs) (H) and IHC of Sox10 of ELNs (I) from EtOH- and MC903-treated CT and Braf/Pten mice at D30. Blue arrow points to one of the Sox10+ melanoma cells. Scale bar: 50 μm. Data are representative of 3 independent experiments with similar results.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts